Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report 2017 - Research and Markets

Research and Markets
Posted on: 09 Nov 17

The "Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report" report has been added to Research and Markets' offering.

A pipeline analysis report, 2017 provides comprehensive insights about pipeline molecules in this approach of treatment. The key objective of the report is to establish the understanding of all the pipeline molecules that fall under stem cell therapy for diabetes and related conditions.

This report provides information on the therapeutic development based on the stem cell therapy for diabetes and related conditions dealing with all the pipeline drugs; comparative analysis at various stages covering Phase II, Phase I/II, and pre-clinical; therapeutics assessment by monotherapy and combination products; and molecule type drug information. The report also covers the company's information involved in the therapeutic development of the products. It also highlights the discontinued and dormant products.

Diabetes is a metabolic disorder. It is a chronic condition associated with high sugar (glucose) level in the blood. Insulin, a hormone produced by the pancreas of the body, lowers the glucose level in the blood. Any defect in insulin secretion, or its action, or both, causes abnormal blood glucose level. Diabetes can be classified into two types, type 1 (insulin-dependent diabetes mellitus or juvenile onset) and type 2 (non-insulin-dependent diabetes mellitus, or adult-onset diabetes). In type 1 diabetes, the body does not produce insulin. In type 2 diabetes, which is the more common type (90%-95%), the body does not make or use insulin well. It can affect all people, regardless of age and sex.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.

Companies Mentioned

  • Athersys
  • Mesoblast
  • Caladrius Biosciences
  • Sanofi
  • Novo Nordisk

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Stem Cell Therapy For Diabetes And Related Conditions: An Insight

Part 04: Major Regulatory Authorities

Part 05: Pipeline Landscape

Part 06: Comparative Analysis

Part 07: Indication Analysis

Part 08: Therapeutic Assessment By Therapy Type

Part 09: Therapeutic Assessment By Roa

Part 10: Key Companies

For more information about this report visit

View source version on

Business Wire

Last updated on: 09/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.